Neoadjuvant ChemotherapyPerioperativeRegimensChemotherapyMetastasisClinical outcomesDefinitivePotentially resectableOverall survivalRetrospectiveDiseaseMethodsStagesTumorTherapyCharacteristicsSupportsUracil and tegafurRadiotherapyCisplatinPostoperativeEfficacyPreoperativeDiseaseMulticenterLocally advanced rectal cancerAcuteSurvivalPatientsProspectiveWangResectionStageTreatmentYears
Neoadjuvant Chemotherapy1
- Perioperative, neoadjuvant chemotherapy or chemoradiotherapy followed by surgery is appropriate. (medscape.com)
Perioperative2
- A study by Fogh et al of induction chemoradiotherapy followed by surgery, a strategy that is widely used in treating esophageal cancer, found that perioperative morbidity and mortality with this approach was not significantly different in patients aged 70 years or older compared with younger patients. (medscape.com)
- Perioperative therapy is common practice, with chemoradiotherapy after surgery showing a clear survival benefit. (medscape.com)
Regimens1
- For chemotherapy, two-drug cytotoxic regimens that include a platinum agent are generally preferred for first-line therapy. (medscape.com)
Chemotherapy7
- To further explore this topic, we retrospectively analyzed the impact of adjuvant chemotherapy on the clinical outcomes of 77 stage II and 117 stage III patients diagnosed between January 2008 and December 2012. (springeropen.com)
- Higher overall survival from adjuvant chemotherapy in stage II patients with node involvement did not reach the level of statistical significance ( P = 0.102). (springeropen.com)
- Data from a recent randomized trial enrolling only patients with II-IIIB gastric cancer revealed a 36 % recurrence rate in 5 years for patients without adjuvant chemotherapy after D2 dissection (Noh et al. (springeropen.com)
- Before 2000, there was no large-scaled randomized phase III trial to evaluate the benefit of adjuvant chemotherapy on the survival of patients with gastric cancer after operation. (springeropen.com)
- Some studies suggested that adjuvant chemotherapy only be recommended for patients with positive lymph node (Earle and Maroun 1999 ), or not recommended because the benefit was small (Janunger et al. (springeropen.com)
- 2002 ). Fortunately, in the last decade, randomized, placebo-controlled, phase III clinical trials have proven the survival advantage conferred by adjuvant chemotherapy after D2 lymph node dissection (Noh et al. (springeropen.com)
- Although intra-arterial chemoradiotherapy (CRT) followed by surgery has been the standard of care for patients with advanced maxillary sinus squamous cell carcinoma (MSSCC), concurrent intra-arterial chemotherapy and high-dose radiotherapy without surgery has emerged as a promising alternative. (brieflands.com)
Metastasis1
- Objectives: To evaluate whether tegafur-uracil maintenance (UFTm) following postoperation adjuvant cisplatin-based concurrent chemoradiotherapy (CCRT) may reduce distant metastasis in patients with resected oral cavity squamous cell carcinoma (OSCC) with pathologic extranodal extension (pENE+). (bvsalud.org)
Clinical outcomes2
- Clinical Outcomes of Intra-arterial Chemoradiotherapy and Neoadjuvant Chemo. (brieflands.com)
- Yunaiyama D, Tsukahara K, Okubo M, Saito K . Clinical Outcomes of Intra-arterial Chemoradiotherapy and Neoadjuvant Chemoradiotherapy Followed by Surgery for Maxillary Sinus Squamous Cell Carcinoma. (brieflands.com)
Definitive1
- This study aimed to identify the optimal treatment regimen for patients with MSSCC by retrospectively reviewing the outcomes of MSSCC patients, who were treated with neoadjuvant intra-arterial chemoradiotherapy (NACR) followed by surgery, as well as patients who received definitive intra-arterial chemoradiotherapy alone. (brieflands.com)
Potentially resectable1
- Stage I, II, and III esophageal cancers are all potentially resectable. (medscape.com)
Overall survival3
- The final analysis of the phase 3 LEAP-002 study did not demonstrate an overall survival (OS) benefit of the addition of pembrolizumab to first-line lenvatinib in patients with advanced hepatocellular carcinoma (HCC). (medicom-publishers.com)
- This study aimed to evaluate the ability of intra-arterial CRT alone to increase the overall survival (OS) of patients with MSSCC. (brieflands.com)
- According to several studies, use of concurrent chemoradiotherapy can improve the locoregional control and overall survival (OS) of patients with locally advanced head and neck carcinomas, compared to radiotherapy alone ( 3 - 5 ). (brieflands.com)
Retrospective2
- Methods: A retrospective comparison was conducted between two cohorts of patients with resected pENE+ OSCC who completed adjuvant CCRT between March 2015 and December 2017, including one cohort of a phase II trial using UFTm and a trial-eligible but off-protocol cohort without using UFTm (non-UFTm) after their adjuvant CCRT. (bvsalud.org)
- This retrospective study was approved by the institutional review board (approval code: T2019-0262), and the requirement for written informed consent was waived. (brieflands.com)
Disease1
- 0.001] for patients with stage III, but not stage II, disease. (springeropen.com)
Methods1
- METHODS: Based on next generation sequencing (NGS) studies, PDX-B13 had CCND1 copy number (CN) gain but CDKN2A CN loss, whereas PDX-Li41 had CDKN2A and RB1 CN loss, TSC1 (negative regulator of mTOR) frameshift deletion mutation, and increased activation of mTOR, a serine/threonine kinase that governs metabolism, autophagy, and apoptosis. (bvsalud.org)
Stages1
- Unlike other head and neck malignancies, maxillary sinus carcinomas are often diagnosed in locally advanced stages ( 2 ), owing to their localization and lack of symptoms in early stages. (brieflands.com)
Tumor1
- RESULTS: Everolimus, an mTOR inhibitor, suppressed tumor growth in the two PDX NPC models and had an additive antitumor effect with palbociclib, a CDK4/6 inhibitor. (bvsalud.org)
Therapy4
- In a phase 1 study, lenvatinib plus pembrolizumab demonstrated promising anti-tumour activity as first-line therapy in unresectable HCC [2]. (medicom-publishers.com)
- The current global, randomised, double-blind, phase 3 LEAP-002 trial ( NCT03713593 ), presented by Prof. Richard Finn (David Geffen School of Medicine, CA, USA) evaluated the efficacy of lenvatinib plus pembrolizumab versus lenvatinib plus placebo as first-line therapy for advanced HCC [3]. (medicom-publishers.com)
- Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). (medicom-publishers.com)
- Tailoring therapy based on different characteristics for patients with stage II gastric cancer may produce better outcomes. (springeropen.com)
Characteristics1
- There were no significant differences regarding the patients' characteristics between the two groups. (brieflands.com)
Supports1
- However, the study supports the potential usefulness of lenvatinib as a standard first-line treatment for advanced HCC. (medicom-publishers.com)
Uracil and tegafur3
- To evaluate the efficacy and toxicity of a novel combination treatment using concurrent radiotherapy with cisplatin plus UFT, which is comprised of uracil and tegafur, in locally advanced non-small cell lung cancer (NSCLC) patients. (aacrjournals.org)
- 4. Preoperative chemoradiotherapy for rectal cancer: randomized trial comparing oral uracil and tegafur and oral leucovorin vs. intravenous 5-fluorouracil and leucovorin. (nih.gov)
- 6. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. (nih.gov)
Radiotherapy10
- UFT plus cisplatin with concurrent radiotherapy is considered to be a feasible and effective treatment for locally advanced NSCLC patients. (aacrjournals.org)
- Recent randomized Phase III trials have shown that concurrent chemoradiotherapy is superior to chemotherapy followed by radiotherapy in terms of the response and survival in such patients (3, 4) . (aacrjournals.org)
- 3. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial. (nih.gov)
- 8. A phase I study of oral UFT given concomitantly with standard preoperative radiotherapy for rectal cancer. (nih.gov)
- 10. Concomitant administration of uracil-tegafur and leucovorin during adjuvant radiotherapy for locally advanced rectal cancer. (nih.gov)
- 11. Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: a phase II multicenter study with 3 years' follow-Up. (nih.gov)
- A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial. (gortec.net)
- Despite the advances in chemotherapy, molecular target agents, immunotherapy, and radiotherapy (RT) techniques, the 5-year overall survival (OS) rate in patients with pancreatic cancer remains unsatisfactory, with a 91% mortality rate in 2018 ( 2 ). (frontiersin.org)
- A meta-analysis, which included 20 studies with 6712 patients, showed that patients with BTC benefited more from adjuvant chemotherapy or chemoradiotherapy than from radiotherapy alone, and that the greatest benefit from adjuvant therapy was observed in patients who underwent R1 resection and/or had lymph node-positive disease [ 4 ]. (biomedcentral.com)
- The patients who met one of the following criteria were excluded: (1) underwent R1 or macroscopically positive margin (R2) resection, (2) died of surgical complications within 3 months after resection, (3) treated with adjuvant radiotherapy or chemoradiotherapy, (4) with another primary cancer at the time of BTC diagnosis, and (5) treated with gemcitabine-based adjuvant chemotherapy. (biomedcentral.com)
Cisplatin2
- In this Phase II trial, patients with unresectable stage III NSCLC were treated with the oral administration of UFT (400 mg/m 2 /d tegafur) on days 1-14 and days 29-42 whereas 80 mg/m 2 cisplatin was administered i.v. on days 8 and 36. (aacrjournals.org)
- Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study. (gortec.net)
Postoperative1
- [ 20 ] Postoperative quality of life has been found to be similar regardless of whether a transhiatal or a transthoracic en bloc resection was performed. (medscape.com)
Efficacy3
- 1. Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis. (nih.gov)
- 15. Efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma when combined with oral tegafur-uracil modulated with leucovorin: results from a phase II study. (nih.gov)
- This study aimed to evaluate the efficacy of a high dose of oral tegafur-uracil (400 mg/m 2 ) plus leucovorin with preoperative chemoradiation of locally advanced rectal cancer and to explore the impact of polymorphisms of cytochrome P 2A6 (CYP2A6), uridine monophosphate synthetase (UMPS), and ATP-binding cassette B1 (ABCB1) on clinical outcome. (nih.gov)
Preoperative8
- 2. Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer. (nih.gov)
- 5. Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer. (nih.gov)
- 7. Prognostic significance of pathological response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer. (nih.gov)
- 9. Phase I/II Study of Preoperative Chemoradiotherapy With TEGAFIRI for Locally Advanced Rectal Cancer. (nih.gov)
- 12. [A Case of Locally Advanced Rectal Cancer with a Pathological Complete Response to Preoperative Chemoradiotherapy]. (nih.gov)
- 16. Tumor volume reduction rate after preoperative chemoradiotherapy as a prognostic factor in locally advanced rectal cancer. (nih.gov)
- Patients with cT3 or cT4 rectal cancer were enrolled and were given tegafur-uracil 400 mg/m 2 /day and leucovorin 90 mg/m 2 /day for 7 days a week during preoperative chemoradiation (50.4 Gy/28 fractions) in this phase II trial. (nih.gov)
- 2. Min-Hsiung Huang, Jen-Kou Lin, Hon-Ki Hsu, Chung-Ping Hsu, Kwang-Yu Chien, and Ming-Jen Hshieh:Preoperative evaluation of resectability of esophageal cancer with CT scan. (joshua-healthcare.com)
Disease4
- For non-small cell lung cancer (NSCLC) patients with unresectable stage III disease and a good performance status, combined chemoradiotherapy is the standard treatment (1, 2) . (aacrjournals.org)
- Patients with locoregional disease (stage I-II), in good medical condition, are offered a curatively intended treatment. (medscape.com)
- A recent randomized prospective trial, comparing en bloc resection with transhiatal resection, suggested improved disease-free 5-year survival in the en bloc group (39 vs 27%), although the difference was not statistically significant (95% confidence interval for the difference: -1-24). (medscape.com)
- [ 12 ] A retrospective case-control study comparing transhiatal with transthoracic en bloc resection in patients with T3 N1 disease showed an improved 5-year survival in the en bloc group. (medscape.com)
Multicenter1
- Patients with thoracic cancer requiring DM pharmacotherapy, who received CDDP (≥ 60 mg/m2)-containing regimens using the short hydration method (n = 140), were enrolled in this retrospective multicenter observational study. (bvsalud.org)
Locally advanced rectal cancer1
- 13. Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study. (nih.gov)
Acute1
- However, concurrent chemoradiotherapy is also associated with an increased rate of bone marrow suppression and acute esophagitis compared with sequential chemoradiotherapy. (aacrjournals.org)
Survival3
- The median survival, the 1- and 2-year survival rates were 16.5 months, 67% and 33%, respectively. (aacrjournals.org)
- [ 14 ] The overall survival rate at 5years was 52%, indicating that long-term survival from adenocarcinoma of the esophagus can be achieved in more than half the patients who undergo en bloc resection. (medscape.com)
- Neoadjuvant chemoradiotherapy appears to be associated with better survival than local therapy or surgery alone. (medscape.com)
Patients7
- Grades 3 non-hematological toxicities were only reported in three patients with nausea, two with esophagitis and one with pneumonitis whereas no grade 4 non-hematological toxicity was observed. (aacrjournals.org)
- This study aimed to determine further risk factors associated with CIN development in DM patients. (bvsalud.org)
- The primary endpoint of the present study was the elucidation of risk factors (patient factors, DM medication influence, and treatment-related factors) associated with CIN development in patients with DM. (bvsalud.org)
- In conclusion, our study revealed that female sex is significantly associated with CIN development in patients with DM and thoracic cancer. (bvsalud.org)
- 100 consecutive patients underwent en bloc esophagectomy for esophageal adenocarcinoma. (medscape.com)
- 14. Pre-operative chemoradiotherapy with UFT and Leucovorin in patients with advanced rectal cancer: a phase II study. (nih.gov)
- A study by Fogh et al of induction chemoradiotherapy followed by surgery, a strategy that is widely used in treating esophageal cancer, found that perioperative morbidity and mortality with this approach was not significantly different in patients aged 70 years or older compared with younger patients. (medscape.com)
Prospective1
- However, its exact role has not been determined due to the lack of randomized, prospective studies. (biomedcentral.com)
Wang1
- 12. Jen-Kou Lin, Chang-Ling Liang, Hung Hsu, Feng-Ming Wang:Anal manometric studies in hemorrhoid and anal fissures. (joshua-healthcare.com)
Resection2
- [ 9 ] The most commonly used approaches for resection of localized esophageal carcinoma are transhiatal and right transthoracic en bloc resection. (medscape.com)
- [ 11 ] Nevertheless, in recent years more compelling data have emerged, suggesting that the more extensive node dissection accomplished with transthoracic en bloc resection is beneficial. (medscape.com)
Stage1
- Stage I, II, and III esophageal cancers are all potentially resectable. (medscape.com)
Treatment1
- Koizumi A, Tamura Y, Yoshida R, Mori C, Ono Y , Tanino M, Mizukami Y , Sasaki T. Two Cases of SMARCA4-Deficient Non-small Cell Lung Cancer (NSCLC) with Improved Performance Status (PS) after Treatment with Immune Checkpoint Inhibitors (ICIs). (or.jp)
Years1
- A study from the Mayo Clinic showed that SF-36 quality of life scores at a median of 5.3 years after esophagectomy were better than the national norm for the role-physical and role-emotional dimensions, but lower for health perception. (medscape.com)